WESTBROOK, Maine, July 25, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today published its 2022 Corporate Responsibility Report, highlighting progress against the environmental, social, and governance (ESG) goals it announced last year. The report also introduces a framework to focus and prioritize the company's ESG goals and initiatives. The framework includes three pillars focused on the environmental and social priorities most important to IDEXX's stakeholders and business, underpinned by strong governance, policies, and systems infrastructure.
The Care We Advance
IDEXX brings clarity to a complex world through diagnostic and software solutions to support longer, fuller lives for pets and those who care for them. Key highlights from the 2022 report include these:
The People We Support
IDEXX strives to foster a collaborative and inclusive workplace that empowers employees to develop and grow and find purpose and fulfillment in all they do. Key highlights from the 2022 report include these:
The Planet We Share
IDEXX is committed to reducing its environmental footprint. Key highlights from the 2022 report include these:
"This year's report coincides with IDEXX celebrating its 40th anniversary," said Jay Mazelsky, IDEXX President and Chief Executive Officer. "I feel a deep sense of pride in how we continue to fulfill our Purpose and create long-term value for our stakeholders by advancing care for people and animals, protecting the planet we share, and supporting colleagues and communities where we live and work."
IDEXX's 2022 report once again focuses on IDEXX's key ESG topics in alignment with reporting standards and frameworks, such as those released by the Sustainability Accounting Standards Board and the Task Force on Climate-Related Financial Disclosures as well as our business strategy. Read the 2022 Corporate Responsibility Report here.
About IDEXX
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs nearly 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit idexx.com.
Last Trade: | US$404.02 |
Daily Change: | -0.63 -0.16 |
Daily Volume: | 931,250 |
Market Cap: | US$33.080B |
February 03, 2025 October 31, 2024 August 21, 2024 August 06, 2024 June 04, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load